Deceased Donors With HIV in the Era of the HOPE Act: Referrals and Procurement
- PMID: 38769982
- PMCID: PMC11104717
- DOI: 10.1097/TXD.0000000000001641
Deceased Donors With HIV in the Era of the HOPE Act: Referrals and Procurement
Abstract
Background: The HIV Organ Policy Equity Act legalizes organ procurement from donors with HIV (HIV D+). A prior survey of Organ Procurement Organizations (OPOs) estimated >2000 HIV D+ referrals/year; however, only 30-35 HIV D+/year have had organs procured. Given this gap, we sought to understand HIV D+ referrals and procurements in practice.
Methods: We prospectively collected data on all OPO-reported HIV D+ referrals, including reasons for nonprocurement. We evaluated trends and compared HIV D+ characteristics by procurement status using regression, chi-squared tests, and Wilcoxon rank-sum tests.
Results: From December 23, 2015 to May 31, 2021, there were 710 HIV D+ referrals from 49 OPOs, of which 171 (24%) had organs procured. HIV D+ referrals increased from 7 to 15 per month (P < 0.001), and the procurement rate increased from 10% to 39% (P < 0.001). Compared with HIV D+ without procurement, HIV D+ with procurement were younger (median age 36 versus 50 y), more commonly White (46% versus 36%), and more often had trauma-related deaths (29% versus 8%) (all P < 0.001). Nonprocurement was attributed to medical reasons in 63% of cases, of which 36% were AIDS-defining infections and 64% were HIV-unrelated, commonly due to organ failure (36%), high neurologic function (31%), and cancer (14%). Nonprocurement was attributed to nonmedical reasons in 26% of cases, commonly due to no authorization (42%), no waitlist candidates (21%), or no transplant center interest (20%).
Conclusions: In the early years of the HIV Organ Policy Equity Act, actual HIV D+ referrals were much lower than prior estimates; however, the numbers and procurement rates increased over time. Nonprocurement was attributed to both medical and nonmedical issues, and addressing these issues could increase organ availability.
Copyright © 2024 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
W.A.W. received consulting fees from AstraZeneca, the Centers for Disease Control and Prevention/Infectious Diseases Society of America COVID-19 Real-Time Learning Network, GlobalData, and advisory board fees from AstraZeneca and Novavax. D.L.S. receives consulting fees from AstraZeneca, Novavax, CareDx, Moderna Therapeutics, Regeneron, and Springer Publishing as well as speaking honoraria from AstraZeneca, CareDx, Optum Health Education, Sanofi, and WebMD. C.M.D. receives honoraria from Gilead Sciences for serving on a grant review committee and Gilead provides drug for several investigator-initiated clinical trials of C.M.D. The other authors declare no conflicts of interest.
Figures
References
-
- Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). Organ procurement and transplantation: implementation of the HIV Organ Policy Equity Act. Final rule. Fed Regist. 2015;80:26464–26467. - PubMed
-
- Richterman A, Sawinski D, Reese PP, et al. . An assessment of HIV-infected patients dying in care for deceased organ donation in a United States urban center. Am J Transplant. 2015;15:2105–2116. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
